Jonathan Douxfils

Professor Jonathan Douxfils graduated in Pharmaceutical Sciences in 2011 and obtained his PhD in Biomedical and Pharmaceutical Sciences in 2015.

In 2017, he founded QUALIblood, a Contract Research Organization (CRO) offering central laboratory services to industries, hospitals and universities for biological investigations. QUALIblood currently employs seven people, working on preclinical and clinical trials in various pharmaceutical fields.

In 2018, Professor Douxfils joined the University of Namur as a member of the academic staff, where he teaches pharmacology to bachelor and master students. He also offers continuing education courses for healthcare professionals, particularly pharmacists and clinical biologists.

In 2023, the University of Namur appointed him Professor and he set up a research unit in clinical pharmacology and toxicology, comprising seven academics and around ten PhD students.

Professor Douxfils works with numerous researchers in industry, hospitals and universities to develop precise and sensitive biomarkers in haemostasis, serology, oncology and, more recently, neurology.

Recognition and commitment

Professor Douxfils has received numerous grants for his research into thrombosis, haemostasis, infectious diseases, oncology and gene therapies. His multidisciplinary approach and expertise in blood biomarkers enable him to work on interconnected projects. He has also worked as a pharmacovigilance expert at the European Medicines Agency, co-chairing the SSC Control of Anticoagulation at the International Society of Thrombosis and Haemostasis (ISTH), and is a member of the Haemostasis Diagnostics expert team at the ECAT and the Belgian Society of Thrombosis and Haemostasis (BSTH). He coordinates the recommendations of the International Council for Standardisation in Haematology (ICSH) on the measurement of oral direct anticoagulants and is an associate editor of several scientific journals.

Thanks to his translational vision of the pharmaceutical market and medical devices, from basic research to post-marketing pharmacovigilance, Professor Jonathan Douxfils is involved in projects aimed at improving the safety and efficacy of therapeutic agents, thereby helping to promote public health.